ANR.ASX: Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Stock	Anatara Lifesciences Ltd (ANR.ASX)
Release Time	31 Jul 2026, 4:46 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Anatara Lifesciences Ltd Q4 FY26 Activities Report

Key Points

Anti-Obesity Project shows potential for weight management
Manuscripts submitted for GaRP project review
Cash at end of quarter was $0.471 million
R&D tax incentive claim lodged with AusIndustry
Company evaluates additional opportunities

Full Summary

Anatara Lifesciences Ltd provided a Quarterly Activities Report for the quarter ending June 2026. The Anti-Obesity Project showed promising results in pre-clinical studies, with a candidate compound, AOC, demonstrating activity in assisting weight reduction. The company is considering an open-label trial for AOC. The GaRP project pre-clinical work and clinical trial manuscripts have been submitted for review and publication. The company's cash at the end of the quarter was $0.471 million. An application for the R&D tax incentive claim was lodged with AusIndustry, expected to result in a rebate of over $300K.

Guidance

Anatara Lifesciences Ltd expects a rebate of over $300K from the R&D tax incentive claim.

Outlook

Anatara Lifesciences Ltd is evaluating additional opportunities and strategic directions within the healthcare sector to enhance its portfolio of projects.